Therefore, to determine the utility of CD34 and Bcl-2 expression as predictive biomarkers, we investigate the relationship between the expression of two biomarkers before NACT and the efficacy of NACT in cervical cancer. This evidence concerns the gene CD34 and cervical cancer.